Vident Investment Advisory, LLC - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 99 filers reported holding LYELL IMMUNOPHARMA INC in Q1 2023. The put-call ratio across all filers is 3.20 and the average weighting 0.7%.

Quarter-by-quarter ownership
Vident Investment Advisory, LLC ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q1 2023$521,824
-32.5%
221,112
-0.7%
0.02%
-41.4%
Q4 2022$772,738
-20.3%
222,691
+68.4%
0.03%
-9.4%
Q3 2022$969,000
+1.5%
132,256
-9.7%
0.03%
+10.3%
Q2 2022$955,000146,4250.03%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q1 2023
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$47,583,10433.50%
Orland Properties Ltd 15,093,969$35,621,76718.69%
Foresite Capital Management IV, LLC 10,000,000$23,600,00012.24%
MIC Capital Management UK LLP 3,060,569$7,222,9431.38%
Alphabet Inc. 5,865,125$13,841,6950.77%
HSG Holding Ltd 3,045,997$7,188,5530.76%
XTX Topco Ltd 286,614$676,4090.14%
Eagle Health Investments LP 100,000$236,0000.05%
BBR PARTNERS, LLC 164,041$387,1370.04%
CORNERCAP INVESTMENT COUNSEL INC 90,172$212,8060.04%
View complete list of LYELL IMMUNOPHARMA INC shareholders